Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Novel therapeutic strategies targeting innate immune responses and early inflammation after stroke.

Shichita T, Ago T, Kamouchi M, Kitazono T, Yoshimura A, Ooboshi H.

J Neurochem. 2012 Nov;123 Suppl 2:29-38. doi: 10.1111/j.1471-4159.2012.07941.x. Review.

2.

[Post-ischemic innate immunity and its application for novel therapeutic strategy targeting brain inflammation].

Ito M, Kondo T, Shichita T, Yoshimura A.

Nihon Rinsho. 2013 Jul;71(7):1291-301. Review. Japanese.

PMID:
23961683
3.

Neural injury following stroke: are Toll-like receptors the link between the immune system and the CNS?

Downes CE, Crack PJ.

Br J Pharmacol. 2010 Aug;160(8):1872-88. doi: 10.1111/j.1476-5381.2010.00864.x. Review.

4.

IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures.

Vezzani A, Maroso M, Balosso S, Sanchez MA, Bartfai T.

Brain Behav Immun. 2011 Oct;25(7):1281-9. doi: 10.1016/j.bbi.2011.03.018. Epub 2011 Apr 5. Review.

PMID:
21473909
5.

Inhibition of toll-like receptor and cytokine signaling--a unifying theme in ischemic tolerance.

Karikó K, Weissman D, Welsh FA.

J Cereb Blood Flow Metab. 2004 Nov;24(11):1288-304. Review.

PMID:
15545925
6.

[DAMPs (damage-associated molecular patterns) and inflammation].

Ooboshi H, Shichita T.

Nihon Rinsho. 2016 Apr;74(4):573-8. Review. Japanese.

PMID:
27333742
7.

Therapeutic benefits of regulating inflammation in autoimmunity.

Nikoopour E, Schwartz JA, Singh B.

Inflamm Allergy Drug Targets. 2008 Sep;7(3):203-10. Review.

PMID:
18782028
8.
9.

Interleukin-17: a novel inflammatory cytokine that bridges innate and adaptive immunity.

Yu JJ, Gaffen SL.

Front Biosci. 2008 Jan 1;13:170-7. Review.

PMID:
17981535
10.

Innate immunity of the ocular surface.

Ueta M, Kinoshita S.

Brain Res Bull. 2010 Feb 15;81(2-3):219-28. doi: 10.1016/j.brainresbull.2009.10.001. Epub 2009 Oct 12. Review.

PMID:
19828129
11.

STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNγ, TLR4 and IL-6 in vascular disease.

Sikorski K, Czerwoniec A, Bujnicki JM, Wesoly J, Bluyssen HA.

Cytokine Growth Factor Rev. 2011 Aug;22(4):211-9. doi: 10.1016/j.cytogfr.2011.06.003. Epub 2011 Jul 12. Review.

PMID:
21752694
12.

Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms.

Loppnow H, Werdan K, Buerke M.

Innate Immun. 2008 Apr;14(2):63-87. doi: 10.1177/1753425908091246. Review.

PMID:
18713724
13.

Direct and indirect role of Toll-like receptors in T cell mediated immunity.

Xu D, Liu H, Komai-Koma M.

Cell Mol Immunol. 2004 Aug;1(4):239-46. Review.

14.

Inflammation as a therapeutic target in acute ischemic stroke treatment.

Tuttolomondo A, Di Sciacca R, Di Raimondo D, Renda C, Pinto A, Licata G.

Curr Top Med Chem. 2009;9(14):1240-60. Review.

PMID:
19849665
15.

Toll-like receptor signaling and regulation of cytokine gene expression in the immune system.

Ozato K, Tsujimura H, Tamura T.

Biotechniques. 2002 Oct;Suppl:66-8, 70, 72 passim. Review.

PMID:
12395929
16.

Innate immune mechanisms in ischemia/reperfusion.

Kaczorowski DJ, Tsung A, Billiar TR.

Front Biosci (Elite Ed). 2009 Jun 1;1:91-8. Review.

PMID:
19482628
17.

Injury and repair mechanisms in ischemic stroke: considerations for the development of novel neurotherapeutics.

Candelario-Jalil E.

Curr Opin Investig Drugs. 2009 Jul;10(7):644-54. Review.

PMID:
19579170
18.

Innate immunity, macrophage activation, and atherosclerosis.

Yan ZQ, Hansson GK.

Immunol Rev. 2007 Oct;219:187-203. Review.

PMID:
17850490
19.

Platelet Toll-like receptor expression: the link between "danger" ligands and inflammation.

Garraud O, Cognasse F.

Inflamm Allergy Drug Targets. 2010 Dec;9(5):322-33. Review.

PMID:
20518724

Supplemental Content

Support Center